Quality of care management decisions by multidisciplinary cancer teams: a systematic review.
Benjamin W Lamb, Katrina F Brown, Kamal Nagpal...
https://pubmed.ncbi.nlm.nih.gov/21442345/Actively Recruiting
Led by Leiden University Medical Center · Updated on 2025-07-02
400
Participants Needed
4
Research Sites
N/A
Total Duration
Researchers are evaluating an Integrated Oncological Decision-making Model IODM designed to tailor cancer treatment plans to individual patients. This study aims to assess how the IODM affects personalized treatment decisions and patient outcomes. The trial uses a stepped-wedge cluster randomized design involving 400 adult patients across eight oncological care paths in four medical centers in the Netherlands. Participants will receive either usual care based on standard clinical guidelines or care using the IODM, which integrates three components current oncological treatment options with their benefits and risks, the patients overall health including physical and emotional functioning, and the patients goals and preferences in treatment and daily life. The study transitions care paths from standard practice to the IODM in randomized steps. Throughout the study, researchers will assess the difference between standard treatment recommendations and actual decisions, focusing on whether these differences reflect more personalized choices. They will also evaluate patient quality of life, frailty, resilience, optimism, decision-making preferences, and patient-centeredness using questionnaires and medical records. The study duration includes the intervention and a 12-month follow-up, totaling around two years.
CONDITIONS
Improving Personalized Treatment in Oncology: Effects of Integrated Oncological Decision-making
L
Lieke Welling, MD PhD (Dr)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Leiden University Medical Center
Lead Sponsor
Dutch Cancer Society
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years including 12-month follow-up
Participants receive oncological care either through the usual care pathway or within the Integrated Oncological Decision-making Model which personalizes treatment decisions by incorporating state-of-the-art treatment options, health status, and patient goals/preferences.
Visits as part of routine oncological care and decision-making consultations
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Benjamin W Lamb, Katrina F Brown, Kamal Nagpal...
https://pubmed.ncbi.nlm.nih.gov/21442345/A M Stiggelbout, A H Pieterse, J C J M De Haes
https://pubmed.ncbi.nlm.nih.gov/26215573/Marije E Hamaker, Marthe Te Molder, Noortje Thielen...
https://pubmed.ncbi.nlm.nih.gov/29631898/Michael A Hussey, James P Hughes
https://pubmed.ncbi.nlm.nih.gov/16829207/M F Scheier, C S Carver
https://pubmed.ncbi.nlm.nih.gov/4029106/Nancy K Janz, Patricia A Wren, Laurel A Copeland...
https://pubmed.ncbi.nlm.nih.gov/15284259/April Reynolds
https://pubmed.ncbi.nlm.nih.gov/19901351/A M O'Connor
https://pubmed.ncbi.nlm.nih.gov/7898294/Elisabeth Hansson, Inger Ekman, Karl Swedberg...
https://pubmed.ncbi.nlm.nih.gov/25595358/Suzanne Festen, Hanneke van der Wal-Huisman, Annya H D van der Leest...
https://pubmed.ncbi.nlm.nih.gov/33342722/Leiden University Medical Center
Lead Sponsor
Dutch Cancer Society
Collaborating Sponsor